BG
ADMS

Bellevue Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Bellevue Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-116,000
Closed -$593K – 226
2019
Q3 		$593K Buy
+116,000
New +$716K 0.01% 153
2017
Q4 		– Sell
-24,000
Closed -$508K – 137
2017
Q3 		$508K Buy
+24,000
New +$440K 0.05% 122

Other funds holding ADMS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Bellevue Group's ADMS Position: Q4 2019 in Review

Bellevue Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 116,000 shares — an estimated $593K sold.

Bellevue Group first reported a position in ADMS in Q3 2017 and held it in 2 quarters. The position peaked at $593K in Q3 2019. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

  • Bellevue Group reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Bellevue Group sold 116,000 Adamas Pharmaceuticals shares in Q4 2019, an estimated $593K.
  • Bellevue Group first reported a position in Adamas Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Bellevue Group's Adamas Pharmaceuticals position peaked at $593K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.